SNDX — Syndax Pharmaceuticals, Inc.

Summary of Syndax Pharmaceuticals Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $172.4 million for 2025, comprising:
  • Revuforj Net Revenue: $124.8 million, with Q4 showing a 38% increase quarter-over-quarter.
  • Niktimvo Collaboration Revenue: $42.4 million from $151.6 million in net revenue reported by partner Incyte.
  • Milestones and Royalties: $5.1 million.
• Cash Position: $394 million in cash, equivalents, and marketable securities at year-end, positioning the company for continued investment without needing additional capital.
• Expense Guidance for 2026: Expected to be stable at approximately $400 million, excluding $50 million in noncash stock compensation.

2. Strategic Updates and Business Highlights

• Product Launches: Successfully launched two first-in-class medicines, Revuforj and Niktimvo, achieving significant market traction.
• Revuforj:
  • Strong demand driven by KMT2A and newly approved NPM1 indications.
  • Approximately 1,050 patients treated commercially since launch, with 50% penetration of the KMT2A incident population.
• Niktimvo:
  • Continued growth with a 22% increase in Q4 revenue, tracking ahead of benchmarks set by competitor REZUROCK.
  • High persistency rates with 60-70% of patients remaining on therapy at month 10.
• Pipeline Advancements:
  • Enrollment completed in pivotal trials for Revuforj and axatilimab, with significant upcoming data readouts expected in 2026.

3. Forward Guidance and Outlook

• Revuforj: Anticipated continued growth, especially with the NPM1 indication expected to triple the addressable patient population.
• Niktimvo: Projected to exceed $200 million in annualized revenue, with significant growth potential in chronic GVHD.
• Clinical Development: Focus on advancing pipeline programs, particularly in IPF and the potential for additional indications for existing therapies.

4. Bad News, Challenges, or Points of Concern

• Competitive Pressures: While Syndax is optimistic about its product profiles, the presence of competitors in the market could impact market share, particularly in the NPM1 space.
• Market Dynamics: The company is still in the early stages of capturing the NPM1 patient population, and while growth is expected, it remains to be seen how quickly they can establish dominance.
• Regulatory Risks: Future clinical trial outcomes and their implications for potential approvals remain uncertain.

5. Notable Q&A Insights

• Post-Transplant Maintenance: Physicians are increasingly comfortable with Revuforj dosing in maintenance therapy, with expectations that 70-80% of patients could resume treatment post-transplant.
• NPM1 Patient Starts: Currently at 30% of new patient starts, with expectations for this to increase as awareness and confidence in Revuforj grow.
• IPF Trial Expectations: Positive outcomes from the ongoing Phase II trial could lead to a swift initiation of a pivotal Phase III trial, with plans to utilize a subcutaneous regimen for improved patient compliance.
• Combination Therapy Trends: Approximately 40% of Revuforj patients are being treated in combination with other therapies, which is expected to enhance treatment durations and overall outcomes.

This summary encapsulates the key aspects of Syndax's Q4 2025 earnings call, highlighting both the achievements and the challenges faced by the company as it navigates a competitive landscape.